ReviewJournal of clinical medicine2025
Promising Molecular Therapeutic Targets for Drug Development in Rheumatoid Arthritis.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potential new targets for rheumatic diseases.EULAR rheumatology open · 2026Review
- OX40L in endothelial cells promotes temporomandibular joint subchondral bone angiogenesis and osteoclastogenesis in mice.Bone & joint research · 2026Article
- Seronegative Rheumatoid Arthritis: A Distinct Immunopathological Entity with Erosive Potential.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic diseases encompass various autoimmune and inflammatory conditions affecting the joints, muscles, and connective tissues. Recent studies have advanced our understanding of the molecular pathogenesis of rheumatic diseases and have led to the identification of several promising therapeutic targets, paving the way for the development of novel drug interventions. This review highlights the latest molecular advances in rheumatoid arthritis, with a particular focus on innovative therapeutic strategies, and presents new perspectives on their management, including cytokines, intracellular signaling pathways, immune checkpoints, and novel cell-based therapies. A better understanding of these targets is essential for developing effective and personalized treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.